Stanford Cancer Institute

斯坦福癌症研究所

• 批准号: 10411074
• 负责人: STEVEN E ARTANDI
• 金额: $ 422.37万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-04 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10411074
• 关键词: Address; Animals; Antineoplastic Agents; Area; Basic Cancer Research; Basic Science; Bass; Biological Sciences; Biomedical Engineering; Biometry; Biostatistics Shared Resource; Boston; CAR T cell therapy; California; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Etiology; Cancer Intervention; Cancer Intervention and Surveillance Modeling Network; Cancer Patient; Catchment Area; CdZnTe; Cells; Child Health; Cities; Clinical; Clinical Data; Clinical Oncology; Clinical Protocols; Clinical Research; Clinical Trials; Communities; Community Outreach; Comprehensive Cancer Center; Consult; County; DCNU; Data; Data Commons; Detection; Development; Diagnosis; Diffuse intrinsic pontine glioma; Disease; Doctor of Philosophy; Early Diagnosis; Electronic Health Record; Engineering; Epidemiology; Faculty; Flow Cytometry; Flow Cytometry Shared Resource; Focused Ultrasound Therapy; Fostering; Funding; Genetic; Genomics; Genomics Shared Resource; Goals; Healthcare; Hematologic Neoplasms; Hematological Disease; Human; Humanities; Image; Immunologic Monitoring; Immunologics; Immunology; Incidence; Individual; Infusion procedures; Institute for Cancer Prevention; Institutes; Investigational Therapies; Investments; Leadership; Malignant Childhood Neoplasm; Malignant Neoplasms; Medical center; Medicine; Mission; Modality; Modeling; Monitor; Multiplexed Ion Beam Imaging; Neuraxis; Patient Care; Patient-Centered Care; Patients; Pediatric Hospitals; Pediatric Oncology; Peer Review; Physicians; Population; Population Heterogeneity; Population Sciences; Positron-Emission Tomography; Prevention; Prevention approach; Process; Proteomics; Proteomics Shared Resource; Protocols documentation; Radiobiology; Recording of previous events; Redwood; Regenerative Medicine; Research; Research Personnel; Research Support; Residual Neoplasm; Resource Sharing; Resources; Risk Assessment; Safety; Schools; Science; Scientist; Signal Recognition Particle; System; Talents; Therapeutic; Tissue Procurements; Tobacco; Training; Training and Education; Translating; Translations; Treatment outcome; Tumor-associated macrophages; Ultrasonic Transducer; United States National Institutes of Health; Universities; Woman; acronyms; anticancer research; base; biomedical informatics; cancer care; cancer clinical trial; cancer imaging; cancer immunotherapy; cancer prevention; cancer risk; cancer stem cell; cancer therapy; clinical application; clinical care; community engagement; data management; diffuse midline glioma; drug discovery; effective therapy; experience; health equity; imaging detection; improved; in-vitro diagnostics; indexing; informatics shared resource; innovation; medical schools; member; new technology; next generation; novel diagnostics; novel strategies; novel therapeutics; outpatient facility; population based; population health; programs; recruit; screening; surveillance network; technology development; treatment services; triple-negative invasive breast carcinoma; tumor

PROJECT SUMMARY – OVERALL The Stanford Cancer Institute (SCI) is an NCI-Designated Comprehensive Cancer Center that integrates key strengths in cancer biology, immunology, genetics, population sciences and clinical oncology with expertise in imaging, engineering and technology development. The translation of basic science discoveries through clinical trials and collaborative team science is a distinguishing feature of the SCI. The SCI has 300 members and includes faculty from 32 Departments and from three Schools (Medicine, Engineering, and Humanities and Sciences) within Stanford University. Seven programs (Cancer Biology and Cancer Stem Cells, Cancer Imaging and Early Detection, Cancer Immunotherapy, Cancer Therapeutics, Hematologic Malignancies, Population Sciences, and Radiation Biology) address basic, translational, clinical, and population-based components of cancer research and are supported by 11 shared resources (Animal Tumor Models, Biomedical Informatics, Bioscience Screening, Biostatistics, Cancer Imaging, Cell Science Imaging, Flow Cytometry, Genomics, Human Immune Monitoring, Proteomics, and Tissue Procurement). With a current NCI funding base of $41.9 million, $33 million in other cancer-related NIH support, $16.4 million in other peer-reviewed cancer-relevant funding and $91.3 million in total peer reviewed funds, the SCI is fulfilling its mission to translate Stanford discoveries into improving the diagnosis, treatment, and outcomes of cancer patients and to better understand cancer etiologies among diverse populations in the Bay Area and beyond. SCI has made major investments in Population Sciences, including the recruitment of a new Associate Director for Population Sciences and the formation of a new Department of Epidemiology and Population Health. We have brought important focus to our catchment area and to health equity through the recruitment of a new Associate Director for Community Outreach and Engagement and the formation of a new SCI Office of Cancer Health Equity and Community Engagement. SCI has developed a highly successful clinical and translational effort in CAR-T therapies bringing new treatments to our patients. Finally, SCI has begun a major initiative in cancer drug discovery uniting cancer scientists, cancer physicians, chemists and engineers across the Stanford campus in their efforts to develop new cancer therapeutics. The SCI, under the new leadership of Steven Artandi, MD, PhD, is requesting CCSG support from the NCI for its critical activities, including in Community Outreach and Engagement, Shared Resources, Cancer Research Training and Education Coordination, Clinical Protocol and Data Management, Protocol Review and Monitoring, Program Leadership, Administration, and Developmental Funds. With new and talented additions to the senior leadership, many new recruitments, and highly effective collaborative interactions, the SCI is poised to further accelerate its contributions to cancer research in the next funding period.

项目概要-总体 斯坦福大学癌症研究所（SCI）是一个国家癌症研究所指定的综合癌症中心， 在癌症生物学、免疫学、遗传学、人口科学和临床肿瘤学方面具有优势， 成像、工程和技术开发。将基础科学发现转化为临床 试验和协作团队科学是SCI的一个显著特征。 SCI有300名成员，包括来自32个系和三个学院（医学， 工程学、人文学和科学）。7个项目（癌症生物学和 癌症干细胞，癌症成像和早期检测，癌症免疫治疗，癌症治疗， 血液肿瘤，人口科学和放射生物学）解决基础，转化，临床， 和基于人群的癌症研究组成部分，并得到11个共享资源的支持（动物肿瘤 模型，生物医学信息学，生物科学筛选，生物统计学，癌症成像，细胞科学成像， 流式细胞术、基因组学、人体免疫监测、蛋白质组学和组织获取）。 目前NCI的资金基础为4190万美元，其他癌症相关的NIH支持为3300万美元， 在其他同行评审的癌症相关资金和9130万美元的同行评审资金中，SCI正在履行 其使命是将斯坦福大学的发现转化为改善癌症的诊断、治疗和预后 患者，并更好地了解湾区及其他地区不同人群的癌症病因。SCI 在人口科学方面进行了重大投资，包括招聘了一名新的人口科学副主任， 人口科学和成立一个新的流行病学和人口健康系。我们有 通过招聘一名新的助理，我们将重点放在了我们的集水区和卫生公平上 社区外展和参与主任以及新的SCI癌症健康办公室的成立 公平和社区参与。SCI在临床和翻译方面取得了非常成功的成果， CAR-T疗法为我们的患者带来新的治疗方法。最后，SCI已经开始在癌症药物方面的重大举措， 联合癌症科学家，癌症医生，化学家和工程师在斯坦福大学校园， 他们致力于开发新的癌症治疗方法。 SCI在Steven Artandi，MD，PhD的新领导下，正在请求NCI的CCSG支持， 其关键活动，包括社区外展和参与，共享资源，癌症研究 培训和教育协调、临床方案和数据管理、方案审查和监测， 项目领导、管理和发展基金。有新的和有才华的补充，以高级 领导，许多新的招聘，以及高效的协作互动，SCI准备进一步 在下一个资助期内加快对癌症研究的贡献。